IXC 8.33% 6.5¢ invex therapeutics ltd

Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-28

  1. 335 Posts.
    lightbulb Created with Sketch. 147
    My understanding is that Prof Sinclair resigned on the Board, but remains in management as the Chief Scientific Officer. https://invextherapeutics.com/directors-management/

    If the remaining BoD members and Tattarang is smart, they will realise that the value of Presendin and Invex's patent portfolio is reliant on Professor Sinclair.

    So if they plan to continue with a scientific program post mid Q3, they will need to create a compelling salary package and incentive program to keep her in the company.
 
watchlist Created with Sketch. Add IXC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.